@文章{信息:doi/10.2196/28630，作者=“Eberle, Claudia and Stichling, Stefanie”，标题=“COVID-19期间管理妊娠糖尿病的远程医疗方法:系统综述”，期刊=“JMIR儿科家长”，年=“2021”，月=“8”，日=“5”，卷=“4”，数=“3”，页数=“e28630”，关键词=“妊娠糖尿病;远程医疗;移动应用程序;COVID-19;系统评价;数字健康;背景:2019年，中国出现了一种新型冠状病毒，由病毒引起的疾病(COVID-19)迅速被列为大流行。患有妊娠期糖尿病(GDM)的孕妇被认为有患严重COVID-19的风险。在大流行的背景下，对于患有GDM的妇女对孕产妇和新生儿结局的不利影响存在严重关切。因此，GDM患者的有效治疗尤为重要。 Due to contact restrictions and infection risks, digital approaches such as telemedicine are suitable alternatives. Objective: This systematic review aims to summarize currently available evidence on maternal and offspring outcomes of pregnant women with GDM and COVID-19 and to examine telemedical interventions to improve maternal glycemic control during the COVID-19 pandemic. Methods: Publications were systematically identified by searching the Cochrane Library, MEDLINE via PubMed, Web of Science Core Collection, Embase, and CINAHL databases for studies published up to March 2021. We sorted the COVID-19 studies by outcome and divided the telemedical intervention studies into web-based and app-based groups. We analyzed case reports (COVID-19) and both randomized and nonrandomized controlled clinical trials (telemedicine). To determine the change in glycated hemoglobin A1c (HbA1c), we pooled appropriate studies and calculated the differences in means, with 95{\%} CIs, for the intervention and control groups at the end of the interventions. Results: Regarding COVID-19 studies, we identified 11 case reports, 3 letters, 1 case series, and 1 retrospective single-center study. In total, 41 patients with GDM and COVID-19 were analyzed. The maternal and neonatal outcomes were extremely heterogeneous. We identified adverse outcomes for mother and child through the interaction of GDM and COVID-19, such as cesarean deliveries and low Apgar scores. Furthermore, we selected 9 telemedicine-related articles: 6 were randomized controlled trials, 2 were clinical controlled trials, and 1 was a quasi-experimental design. In total, we analyzed 480 patients with GDM in the intervention groups and 494 in the control groups. Regarding the quality of the 9 telemedical studies, 4 were rated as strong, 4 as moderate, and 1 as weak. Telemedical interventions can contribute to favorable impacts on HbA1c and fasting blood glucose values in the context of the COVID-19 pandemic. Meta-analysis revealed a mean difference in HbA1c of --0.19{\%} (95{\%} CI 0.34{\%} to 0.03{\%}) for all telemedical interventions, --0.138{\%} (95{\%} CI --0.24{\%} to --0.04{\%}) for the web-based interventions, and --0.305{\%} (96{\%} CI --0.88{\%} to 0.27{\%}) for the app-based interventions. Conclusions: Telemedicine is an effective approach in the context of COVID-19 and GDM because it enables social distancing and represents optimal care of patients with GDM, especially with regard to glycemic control, which is very important in view of the identified adverse maternal and neonatal outcomes. Further research is needed. ", issn="2561-6722", doi="10.2196/28630", url="https://pediatrics.www.mybigtv.com/2021/3/e28630", url="https://doi.org/10.2196/28630", url="http://www.ncbi.nlm.nih.gov/pubmed/34081604" }